Cure for sickle cell diseases inches closer with launch of gene therapy trial

Credit: Tim Vernon/Science Photo Library
Credit: Tim Vernon/Science Photo Library

For 65 years, scientists have known the cause of sickle cell disease but have been unable to cure it without a bone marrow transplant. By fixing the underlying genetic problem… new research buoys hopes for thousands of suffering people — and opens up the possibility of treating other simple inherited disorders.

The study, which will take four years, plans to enroll its first patients this fall. It will start with six adult patients between the ages of 18 and 35 who are very sick. 


While trials at other universities have successfully added extra copies of the healthy gene, or knocked out the bad gene, the new trial is a gene “knock-in.” It is very targeted — replacing the defective gene with a repaired version.

Follow the latest news and policy debates on agricultural biotech and biomedicine? Subscribe to our newsletter.

In the lab, not every bad blood cell must be repaired. The team is currently correcting about 20% to 25% of the genes. The goal is to boost efficiency and correct at least 40% of the blood stem cells.

“It will hopefully reconstitute a blood system that no longer makes a significant number of sickle red blood cells,” said [researcher Mark] Walters. “The sickle mutation is gone and the regular healthy hemoglobin is made in its stead.”


Read the original post

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend